NCPC’s main businesses covers: over 590 varieties, ranging from antibiotic bulks and formulations, vitamins and nutrition products, biotech products, immunosuppressant, and pesticide to veterinary drugs; the annual sales volume for antibiotic bulks is up to 8,000 tons, for vitamins is 23,000 tons, for antibiotic intermediates is up to 5,000 tons, and for formulations amounts to 4.1 billion vials/tablets/capsules; and the main products now occupies a considerably big share of the domestic market. The output and sales volume of Penicillin, Amoxicillin, and Streptomycin sulfate, Cefradine, 7-ADCA, Vitamin C and Vitamin B12 are ranking in the forefront of the world.
Antibiotics are still the core products in NCPC. During her 50 years, NCPC has accumulated its own advantages in antibiotics field, which ensures both its production scale and technology to take lead at home. Dozens of new antibiotics have been developed. At present, NCPC is the second largest penicillin enterprise of the world, and is the largest manufacture of Penicillin, Amoxicillin, Streptomycin, Cefradine, 6-APA and 7-ADCA in China.
Development of bio-pharmacy is NCPC’s new strategic orientation. Utilizing its technological advantages accumulated in the field of traditional fermentation (antibiotics) since 1984, NCPC has initiated modern biotech research and set up a bio-tech drugs development system involving new products R&D, pilot scale and industrialization. At present G-CSF, GM-CSF, EPO and Gene tic Engineering Hepatitis B Vaccines have been launched into the market..